Quarterly and Yearly EBITDA Momentum
Combined adjusted EBITDA for Q4 was $336.1M versus $289.0M in Q4 2024 (+16.3%) and $245.0M last quarter; core ingredients EBITDA for Q4 was $278.2M versus $230.0M in Q4 2024 (+21.0%). For fiscal year 2025, core ingredients EBITDA was $922M versus $790M in 2024 (+16.7%).
Revenue, Volumes and Margin Expansion
Total net sales in Q4 were $1.7B versus $1.4B in Q4 2024 (+21.4%). Raw material volume in Q4 rose to 4.1M metric tons from 3.8M (+7.9%), and quarterly gross margin improved to 25.1% from 23.5% a year ago (+1.6 percentage points).
Feed and Food Segment Strength
Feed segment Q4 EBITDA rose to $193M from $150M in Q4 2024 (+28.7%), with sales of $1.13B versus $924M (+22.3%) and margin up to 24.6% from 22.6% (+2.0 pp). Food segment Q4 sales increased to $429M from $362M (+18.5%) and EBITDA to $82M from $64M (+28.1%), with gross margin 27.2% vs 25.7% (+1.5 pp).
Operational Execution and Product Momentum
Management highlighted four consecutive quarters of margin expansion in Feed, best-in-class operational performance at DGD in Q4 (DGD EBITDA of ~$57.9M or $0.41/gal in Q4), increasing global collagen/gelatin demand, and early commercial traction for higher-value NexData product launches (GLP-1 alternative and upcoming Brain Health product).
Balance Sheet and Liquidity Improvements
Net debt (debt net of cash) improved to ~$3.8B from ~$4.0B (≈$200M reduction, ~5%); preliminary bank covenant leverage ratio improved to 2.9x from 3.9x a year ago (-1.0x). Revolver availability ~ $1.3B and FY capex was $380M with Q4 capex $156M.
Strategic M&A and Portfolio Actions
Darling was the stalking horse bidder for three Potense Group rendering assets in Brazil; expected purchase price around $120M to be funded from Q1 cash flows. Management is advancing a joint venture with PB Leiner and Tessenderlo (regulatory reviews underway) and signaling deliberate portfolio rationalization and possible targeted asset sales.